Healthcare and pharma ad spending in the US will eclipse $30 billion in 2024, up 5% year-over-year:pharma accounting for nearly 90% of this spending
Pharma spent $19.45 billion on online marketing in 2024—88% of the industry’s total digital ad spending.
Prescription drug advertising specifically, more than $10.1 billion spent marketing all prescription drugs in 2024, a year-over-year increase of about 2%.
American pharma industry invested $6.88 billion on direct-to-consumer (DTC) advertising in 2021.
Big Pharma’s advertising spending in the U.S. remains at unprecedented levels, with the top ten pharmaceutical companies alone spending approximately $13.8 billion on advertising and promotion in 2023.
This figure is driven largely by direct-to-consumer (DTC) advertising, which is permitted only in the U.S. and New Zealand.
The top 10 drugmakers increased their TV commercial spending by about 30% year-over-year in Q1 2025
Tax deductions for these drug marketing expenses result in a federal tax revenue loss of $1.5 to $1.7 billion per year, effectively meaning taxpayers subsidize these ads.
Direct to consumer advertising is linked to increased drug prices and can encourage use of high-cost branded medications over generics or less expensive alternatives.
Big Pharma’s aggressive advertising practices contribute to higher drug costs.